From the different combinations that were tested we observed that patients with a high FOXP3 stroma/ CD4 tumor expression ratio have reduced PFS (19.4 vs. 37.8 months, p = 0.013) and OS (46.6 vs. 81.2 months, p = 0.012; Figure 3A-3B; Table 2). This evidence concerns the gene FOXP3 and neoplasm.